ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.117,42
0,26%
Brent Oil
83,76
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prevail Therapeutics Inc (PRVL)

  7. Prevail Therapeutics Inc (PRVL) Notícias

PRVL

Prevail Therapeutics (PRVL)

Prevail Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRVL
DataHoraFonteTítuloCódigoCompanhia
16/02/202118:43Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PRVLPrevail Therapeutics Inc
01/02/202108:41Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202118:16Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:PRVLPrevail Therapeutics Inc
29/01/202108:13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRVLPrevail Therapeutics Inc
27/01/202108:12Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PRVLPrevail Therapeutics Inc
26/01/202119:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202118:39Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202111:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202111:03Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:PRVLPrevail Therapeutics Inc
22/01/202110:55PR Newswire (US)Lilly Completes Acquisition of Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
20/01/202109:01Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:PRVLPrevail Therapeutics Inc
20/01/202108:44Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202010:50Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202010:34Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:PRVLPrevail Therapeutics Inc
22/12/202009:08Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202019:05Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202009:35Dow Jones NewsLilly Raises 2020 Guidance, Sets 2021 OutlookNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202009:17Dow Jones NewsLilly to Buy Prevail Therapeutics for Up to $1.04 BillionNASDAQ:PRVLPrevail Therapeutics Inc
15/12/202008:39Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:PRVLPrevail Therapeutics Inc
15/12/202008:15PR Newswire (US)Lilly Announces Agreement to Acquire Prevail TherapeuticsNASDAQ:PRVLPrevail Therapeutics Inc
11/12/202009:00GlobeNewswire Inc.Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of...NASDAQ:PRVLPrevail Therapeutics Inc
30/11/202009:00GlobeNewswire Inc.Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal DementiaNASDAQ:PRVLPrevail Therapeutics Inc
18/11/202021:01GlobeNewswire Inc.Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202009:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRVLPrevail Therapeutics Inc
13/11/202009:00GlobeNewswire Inc.Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business HighlightsNASDAQ:PRVLPrevail Therapeutics Inc
10/11/202009:00GlobeNewswire Inc.Prevail Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:PRVLPrevail Therapeutics Inc
02/11/202009:00GlobeNewswire Inc.Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEONASDAQ:PRVLPrevail Therapeutics Inc
27/10/202008:00GlobeNewswire Inc.Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher DiseaseNASDAQ:PRVLPrevail Therapeutics Inc
18/09/202016:04GlobeNewswire Inc.Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech SummitNASDAQ:PRVLPrevail Therapeutics Inc
11/09/202009:29Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PRVLPrevail Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRVL

Seu Histórico Recente

BIT
UC4VET
Unicredit Bank
LATK
ROTOETH
RotoHive
NASDAQ
AAZDKXX
Bank of Montreal Autocal...
LSE
0OL9
Interwood Xylemporia Atene
GATE
TOOLSUSDT
TOOLS
LSE
62ML
St. Kuwait 27s
NASDAQ
VXUP
COIN
OUSDEUR
Origin Dollar
COIN
RSCBTC
Resource Coin
NASDAQ
AAXOUXX
JPMorgan Chase Financial...
LSE
70WF
Sampo Bk.25
KUCN
GSTUSDT
GST [Green Satoshi Token]
FX
USDXAF
US Dollar vs XAF
NASDAQ
FRWQTX
S&P MidCap 400 Dividend ...
BIT
UV4KSL
Unicredit Bank
EU
AENAC
Akuo Energy 4.25% 08dec2...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados